Prostate gland is situated in the pelvis below the bladder. Prostate cancer is the medical condition which is an unbounded and unusual growth of cells in the prostate glands of the male. Growth of healthcare expenditure and innovation of new technologies in minimally invasive surgeries to patients due to early post-operative recovery are also likely to driven the global prostate cancer diagnostics market growth.
Rise in prevalence of prostate cancer is key driving factor which is expected boost the global prostate cancer diagnostics market growth. For instant, as per the National Cancer Institute in United State around 174,650 new cases were diagnosed in year 2019. Furthermore, growing technological advancements in diagnostic tests are expected to further propel the global prostate cancer diagnostics market growth over the forecast period. Also, increase in government support and initiatives to develop new technologies to enhance diagnosis will positively influence the market growth. The increase in number of number of new market entrants is another driving factor anticipated to drive the market growth in near future. In addition to that, increase in product approvals by USFDA is projected to support the global prostate cancer diagnostics market growth.
The high cost of prostate cancer drugs is the major restrain which is expected to hinder the global prostate cancer diagnostics market growth. Also, low success rate of clinical trials will affect the global prostate cancer diagnostics market growth over the forecast period.
Global Prostate Cancer Diagnostics Market is segmented into type such as Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others, by diagnosis, such as Tissue Biopsy, Transrectal Ultrasound, Clinical Laboratory Examination, Urine Testing, and Prostate Specific Antigen Testing. Further, market is segmented into treatment such as Surgery, Radiation Therapy, and Therapeutics (Hormone Therapy, Chemotherapy, and Others).
Also, Global Prostate Cancer Diagnostics Market is segmented five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Various key players are discussed in this report including Abbott, MDxHealth, Genomic Health, 3D Signatures, OPKO Health, INC., Siemens Healthcare GmbH, DiaSorin S.p.A, F. Hoffman La Roche Ltd., BioMerieux SA, Beckman Coulter, INC., and Myriad Genetic Inc.
By Diagnosis Tissue Biopsy Transrectal Ultrasound Clinical Laboratory Examination Urine Testing Prostate Specific Antigen Testing
By Treatment Surgery Radiation Therapy Therapeutics Hormone Therapy Chemotherapy Others
By Region North America Latin America Europe Asia Pacific Middle East & Africa
What are the Key Opportunities in Global Prostate Cancer Diagnostics Market?
What will be the growth rate from 2019 to 2030?
Which segment/region will have highest growth?
What are the factors that will impact/drive the Market?
What is the competitive Landscape in the Industry?
What is the role of key players in the value chain?
What are the strategies adopted by key players?
1 Introduction 1.1 Objective of the Study 1.2 Market definition 1.3 Market Scope
2 Research Methodology
2.1 Data Mining 2.2 Validation 2.3 Primary Interviews 2.4 List of Data Sources
3 Executive Summary 4 Global Prostate Cancer Diagnostics Market Outlook 4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis
5 Global Prostate Cancer Diagnostics Market, By Type 5.1 Y-o-Y Growth Comparison, By Type
5.2 Global Prostate Cancer Diagnostics Market Share Analysis, By Type
5.3 Global Prostate Cancer Diagnostics Market Size and Forecast, By Type 5.3.1 Benign Prostatic Hyperplasia
5.3.2. Prostatic Adenocarcinoma
5.3.3 Small Cell Carcinoma
5.3.4 Others
6 Global Prostate Cancer Diagnostics Market, By Diagnosis 6.1 Y-o-Y Growth Comparison, By Diagnosis
6.2 Global Prostate Cancer Diagnostics Market Share Analysis, By Diagnosis
6.3 Global Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis 6.3.1 Tissue Biopsy
6.3.2 Transrectal Ultrasound
6.3.3 Clinical Laboratory Examination
6.3.4 Urine Testing
6.3.5 Prostate Specific Antigen Testing
7 Global Prostate Cancer Diagnostics Market, By Treatment 7.1 Y-o-Y Growth Comparison, By Treatment
7.2 Global Prostate Cancer Diagnostics Market Share Analysis, By Treatment
7.3 Global Prostate Cancer Diagnostics Market Size and Forecast, By Treatment 7.3. 1 Surgery
7.3.2. Radiation Therapy
7.3.3. Therapeutics
7.3.3.1 Hormone Therapy
7.3.3.2 Chemotherapy
7.3.3.3 Others
8Global Prostate Cancer Diagnostics Market, By Region 8.1 Global Prostate Cancer Diagnostics Market Share Analysis, By Region
8.2 Global Prostate Cancer Diagnostics Market Share Analysis, By Region
8.3 Global Prostate Cancer Diagnostics Market Size and Forecast, By Region
9 North America Prostate Cancer Diagnostics Market Analysis and Forecast (2020-2030) 9.1 Introduction
9.2 North America Prostate Cancer Diagnostics Market Share Analysis, By Type
9.3 North America Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis
9.4 North America Prostate Cancer Diagnostics Market Size and Forecast, By Treatment
9.5 North America Prostate Cancer Diagnostics Market Size and Forecast, By Country
9.5.1 U.S. 9.5.2 Canada 9.5.3 Mexico
10EuropeProstate Cancer Diagnostics Market Analysis and Forecast (2020-2030) 10.1 Introduction
10.2 Europe Prostate Cancer Diagnostics Market Share Analysis, By Type
10.3 Europe Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis
10.4 Europe Prostate Cancer Diagnostics Market Size and Forecast, By Treatment
10.5 Europe Prostate Cancer Diagnostics Market Size and Forecast, By Country
10.5.1 Germany 10.5.2 France 10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Prostate Cancer Diagnostics Market Analysis and Forecast (2020-2030) 11.1 Introduction
11.2 Asia Pacific Prostate Cancer Diagnostics Market Share Analysis, By Type
11.3 Asia Pacific Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis
11.4 Asia Pacific Prostate Cancer Diagnostics Market Size and Forecast, By Treatment
11.5 Asia Pacific Prostate Cancer Diagnostics Market Size and Forecast, By Country
11.5.1 China 11.5.2 Japan 11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Prostate Cancer Diagnostics Market Analysis and Forecast (2020-2030) 12.1 Introduction
12.2 Latin America Prostate Cancer Diagnostics Market Share Analysis, By Type
12.3 Latin America Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis
12.4 Latin America Prostate Cancer Diagnostics Market Size and Forecast, By Treatment
12.5 Latin America Prostate Cancer Diagnostics Market Size and Forecast, Country
13Middle East Prostate Cancer Diagnostics Market Analysis and Forecast (2020-2030) 13.1 Introduction
13.2 Middle East Prostate Cancer Diagnostics Market Share Analysis, By Type
13.3 Middle East Prostate Cancer Diagnostics Market Size and Forecast, By Diagnosis
13.4 Middle East Prostate Cancer Diagnostics Market Size and Forecast, By Treatment
13.5 Middle East Prostate Cancer Diagnostics Market Size and Forecast, By Country
14Competitive Analysis 14.1 Competition Dashboard 14.2 Market share Analysis of Top Vendors 14.3 Key Development Strategies
15Company Profiles
15.1 Abbott
15.1.1 Overview 15.1.2 Offerings 15.1.3 Key Financials 15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 MDxHealth
15.2.1 Overview 15.2.2 Offerings 15.2.3 Key Financials 15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Genomic Health
15.3.1 Overview 15.3.2 Offerings 15.3.3 Key Financials 15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 3D Signatures
15.4.1 Overview 15.4.2 Offerings 15.4.3 Key Financials 15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 OPKO Health, INC
15.5.1 Overview 15.5.2 Offerings 15.5.3 Key Financials 15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Siemens Healthcare GmbH 15.6.1 Overview 15.6.2 Offerings 15.6.3 Key Financials 15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 DiaSorin S.p.A, F.
15.7.1 Overview 15.7.2 Offerings 15.7.3 Key Financials 15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Hoffman La Roche Ltd
15.8.1 Overview 15.8.2 Offerings 15.8.3 Key Financials 15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 BioMerieux SA
15.9.1 Overview 15.9.2 Offerings 15.9.3 Key Financials 15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Beckman Coulter, INC
15.10.1 Overview 15.10.2 Offerings 15.10.3 Key Financials 15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
15.11 Myriad Genetic Inc
15.11.1 Overview 15.11.2 Offerings 15.11.3 Key Financials 15.11.4 Business Segment & Geographic Overview
15.11.5 Key Market Developments
15.11.6 Key Strategies
